Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Ownership Capital B.V.

Ownership Capital B.V. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,865 shares of the medical research company's stock after selling 41,532 shares during the quarter. Thermo Fisher Scientific comprises about 5.1% of Ownership Capital B.V.'s portfolio, making the stock its 10th biggest holding. Ownership Capital B.V. owned approximately 0.06% of Thermo Fisher Scientific worth $110,898,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of TMO. Cypress Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $253,000. Intact Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares during the period. GAMMA Investing LLC boosted its stake in shares of Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the period. Deutsche Bank AG boosted its stake in shares of Thermo Fisher Scientific by 9.5% in the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares during the period. Finally, Hancock Whitney Corp raised its holdings in Thermo Fisher Scientific by 0.6% in the fourth quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMO. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Argus cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Finally, Royal Bank Of Canada cut their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $600.30.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $4.29 during midday trading on Friday, reaching $435.02. The stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,995,412. The stock has a market cap of $164.22 billion, a P/E ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The firm has a fifty day simple moving average of $409.16 and a two-hundred day simple moving average of $477.24. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.11 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.